1月12日 - ** 药物开发商Lyra Therapeutics LYRA.O的股价盘前大跌39%至2.28美元
** LYRA表示将停止开发用于治疗慢性鼻炎（一种鼻腔和鼻窦炎症）的主导药物LYR-210 (link)
** 称将裁减大部分员工；保留首席执行官和首席财务官作为顾问
** 聘请 SSG Capital Advisors 探索战略替代方案 - LYRA
** 该公司在 6 月报告了 LYR-210 的积极后期试验数据后采取行动 (link)，推动股价上涨了 300% 以上
** 截至9月30日，LYRA拥有2,210万美元现金，预计剩余资金将持续到2026年第三季度
** 2025 年股价下跌 71.5%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.